No Data
Shenzhou Cell 2024 Annual Results Pre-Profit Announcement
Shenzhou Cell (688520.SH): The net profit is expected to be between 90 million yuan and 0.13 billion yuan for 2024.
On January 17, Glonghui reported that Shenzhou Cell (688520.SH) announced its annual performance pre-profit notice for 2024, expecting the company to achieve a net income attributable to the parent company's owners of 90 million to 130 million yuan, a change from a loss of -396.0183 million yuan in the same period last year. It is expected that the company's net income attributable to the parent company's owners, after deducting non-recurring gains and losses, will be between 450 million and 490 million yuan for the year 2024.
Sinocelltech Group Limited (SHSE:688520) CEO Liangzhi Xie, the Company's Largest Shareholder Sees 4.7% Reduction in Holdings Value
Shenzhou Cell (688520.SH): The company has not laid out in the development of new stem cell products and regenerative medicine.
On November 15, Gelonghui reported that Shenzhou Cell (688520.SH) investor relations activity record shows that the company has no layout in stem cell new product development and regenerative medicine.
Shenzhou Cell (688520.SH): The SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage.
Gelonghui November 15th 丨 Investor Relations Activity Record of Shenzhou Cell (688520.SH) shows that SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage, with no other indications currently planned for market approval.
Shenzhou Cell (688520.SH): Plans to conduct perpetual bond financing of no more than 0.8 billion yuan with its controlling shareholder, Lasa Ailik.
Gelonghui November 15th | The investor relations activity record of Shenzhou Cell (688520.SH) shows that the company plans to conduct perpetual debt financing of no more than 0.8 billion yuan to the controlling shareholder Lhasa Ailik. The proposal for this perpetual debt financing has been approved at the twelfth meeting of the second session of the board of directors and the second extraordinary general meeting of shareholders in 2024. The perpetual debt financing funds are expected to be in place by the end of 2024, which will guarantee the company's net assets turning positive.
Subdued Growth No Barrier To Sinocelltech Group Limited's (SHSE:688520) Price
No Data
